OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
17
Results
Show all
Save search
Copy query
Show results for
Unknown
(17)
Publication Date
Release Date
2021
(5)
2018
(3)
2023
(2)
2025
(1)
2022
(1)
2020
(1)
2019
(1)
2016
(1)
2014
(1)
2002
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene.
Not available
S-EPMC186618
|
biostudies-literature
Cite
Disease-causing variants in TCF4 are a frequent cause of intellectual disability: lessons from large-scale sequencing approaches in diagnosis.
Not available
S-EPMC6018712
|
biostudies-literature
Cite
Proteasome subunit PSMC3 variants cause neurosensory syndrome combining deafness and cataract due to proteotoxic stress.
Not available
S-EPMC7338805
|
biostudies-literature
Cite
Rare De Novo Missense Variants in RNA Helicase DDX6 Cause Intellectual Disability and Dysmorphic Features and Lead to P-Body Defects and RNA Dysregulation.
Not available
S-EPMC6731366
|
biostudies-literature
Cite
Heatwave-associated
Vibrio
infections in Germany, 2018 and 2019.
Not available
S-EPMC8518310
|
biostudies-literature
Cite
Genome sequencing for the diagnosis of intellectual disability as a paradigm for rare diseases in the French healthcare setting: the prospective DEFIDIAG study.
Not available
S-EPMC12495801
|
biostudies-literature
Cite
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.
Not available
S-EPMC6221579
|
biostudies-literature
Cite
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
Not available
S-EPMC8362592
|
biostudies-literature
Cite
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Not available
S-EPMC7727327
|
biostudies-literature
Cite
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets